|
Use of AI and automation among key market trends observed by Entod Pharma as part of decision-making process
|
|
Shardul Nautiyal, Mumbai
December 26 , 2023
|
|
|
Entod Pharmaceuticals has observed that continued use of artificial intelligence (AI) and automation has become a critical trend in pharmaceutical industry, acknowledging that 2023 marked the year of AI, and it expects this trajectory to persist in 2024.
Entod is closely monitoring several key market trends and dynamics that significantly influence its decision-making processes in the pharmaceutical manufacturing sector.
“Generative AI, specifically in drug discovery, has emerged as a valuable tool, enabling researchers to design new molecules and optimize drug candidates more efficiently. This insight directly influences Entod's R&D strategies and resource allocation, ensuring a continued focus on integrating advanced technologies for enhanced efficiency and innovation,” informed Nikkhil K Masurkar, CEO, Entod Pharmaceuticals.
Masurkar further added that flexibility in manufacturing for personalized medicine is another trend that Entod closely monitors. With advances in genomics allowing for the development of personalized drugs, the company recognizes the need for flexible manufacturing facilities. Insights into this trend influence Entod's investment decisions, directing resources toward technologies that enable the production of small batches of personalized drugs and the implementation of flexible manufacturing processes.
Real-world data integration is also a pivotal dynamic for Entod. The company recognizes the increasing importance of real-world data in drug development, going beyond traditional clinical trials. Insights from electronic health records (EHRs) and other sources provide a more comprehensive understanding of drug performance in real-world settings.
The company acknowledges the global trend toward greater transparency, quality assurance, and traceability in the pharmaceutical supply chain. Insights into these regulatory shifts influence Entod's adoption of technologies like blockchain for data transparency, compliance, and real-time monitoring, ensuring adherence to evolving regulatory standards.
Lastly, health equity and accessibility have become central trends for Entod. The company is actively responding to the growing awareness of health disparities by working to reduce the cost of production and improve the affordability of its medicines. These insights shape Entod Pharmaceuticals decision-making processes, leading to investments in research and development aimed at creating drugs that are not only effective but also accessible to a broader population.
Entod Pharmaceuticals employs a proactive strategy to navigate the dynamic regulatory landscape in the healthcare industry, ensuring compliance with evolving regulations.
Key measures include maintaining a dedicated regulatory affairs team, conducting regular training programs for staff, establishing strategic partnerships with regulatory experts, leveraging technological solutions for compliance management, adhering to global compliance standards, conducting internal audits and assessments, engaging with regulatory authorities, implementing robust risk management strategies, and fostering a culture of ethical conduct. These measures collectively enable Entod Pharmaceuticals to stay informed, adapt swiftly to regulatory changes, and uphold the highest standards of compliance in its healthcare operations.
Talking about product portfolio, Masurkar said that there are several innovative products in the pipeline planned for launch in early 2024. Solfactom- a novel silicone-based broad spectrum SPF 50 ultra matte sunscreen gel designed for both the face and body is expected to be launched in January 2024 in our dermatology division. This novel sunscreen incorporates the groundbreaking proprietary cross-linked silicone matrix technology called Silcros that enhances sunscreen potency and duration of action with better spreadability across the skin. Sudagon ER is a unique once-a-day non-sedative therapy for allergic rhinitis and nasal congestion that will be launched in our ENT division. Two of our eye medicines intended for conditions like refractive disorders such as myopia and presbyopia are currently under phase 3 clinical trials in the final stages and shall be launched during the first half of 2024.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|